Tobias Maurer, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany talks on the use of radioligand therapy for treatment of metastatic castration-resistant prostate cancer (mCRPC). Though an effective, well-tolerated and safe treatment in patients with later-stage mCRPC, Dr Maurer comments on issues relating to the availability of radiochemicals and trained personnel to deliver this form of therapy. Moreover, Dr Maurer discusses the future use of PSMA radioligand therapy, such as for the early treatment of prostate cancer, as investigated in the Phase I/II LuTectomy trial (NCT04430192). This interview took place at the European Association of Urology (EAU) Meeting 2022.